

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Shudong Wang *et al.*

Serial No.: 10/810,767

Filed: March 26, 2004

For: N-(4-(4-Methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as Antiproliferative Compounds

Attorney Docket No.: CCI-029CNRCE2

Group Art Unit: 1624

Examiner: Deepak Rao

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL

Dear Sir:

This is in response to the final Office Action mailed from the United States Patent and Trademark Office in the above referenced patent application on September 10, 2007. A Request for Continued Examination and the requisite fees are filed concurrently herewith. No extension of time is required at this time.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.